NASH-focused medtech company DIAFIR appoints Mr. Richard Guillaume to its BOD

RENNES, FRANCE — DIAFIR, a medical technology company focused on the development, manufacture and sale of innovative diagnostic solutions in nonalcoholic steatohepatitis (NASH) and septic arthritis announces today the appointment of Mr Richard Guillaume to its Board of Directors.